RDNT RadNet, Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.…
Industry Peers
Diagnostics & ResearchKey Statistics
About RadNet (NASDAQ: RDNT)
›
RadNet (NASDAQ: RDNT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 12,000 employees.
The shares were at 69.51 USD on 19 November 2026, down 11.0% over 52 weeks. Its 52-week range is 50.82 USD to 85.84 USD: the price is 19.0% below the high and 36.8% above the low.
Its market capitalisation is 5.48B USD.
RadNet reports return on equity of -1.7%, an operating margin of 4.7% and revenue up 22.1% year over year.
Its debt exceeds its cash by 1.42B USD, a debt-to-equity ratio of 1.71. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 97.00 USD is 39.5% above the current price. The next earnings report is expected on 25 February 2027.